Mixed Dyslipidemia: Clinical Trials

22 trials for Mixed Dyslipidemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 3 terminated, 2 recruiting, 1 not yet recruiting. 22 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 322Completed 16, Terminated 3, Recruiting 2, Not yet recruiting 1

Follow Mixed Dyslipidemia: new trials by email Literature Review of Mixed Dyslipidemia trials Research Report on Mixed Dyslipidemia

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
Bempedoic acid, Ezetimibe, Rosuvastatin - Coronary Atherosclerosis, Mixed Dyslipidemia
Phase 3Not yet recruitingDaiichi Sankyo1032026-09-302026-09-29
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
Obicetrapib 10 mg/Bempedoic Acid Placebo, Bempedoic Acid 180mg/Placebo Obicetrapib - Mixed Dyslipidemia, Hypercholesterolaemia
Phase 3RecruitingA. Menarini International Licensing S.A.4262026-05-062026-06-09
Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A
DW5421A, DW5421B Placebo, DW5421B - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3CompletedDaewon Pharmaceutical Co., Ltd.1842025-04-212026-03-06
A Study to Evaluate the Efficacy and Safety of AD-218
AD-218, AD-218A - Mixed Dyslipidemia
Phase 3RecruitingAddpharma Inc.5202022-07-272025-02-05
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
evolocumab, placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3TerminatedAmgen2592019-05-092023-03-27
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
Evolocumab, Placebo to Evolocumab - Hypercholesterolemia, Mixed Dyslipidemia
Phase 3CompletedAmgen4242016-05-172018-08-31
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
Evolocumab AMD, Evolocumab AI/pen - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3CompletedAmgen1642013-07-112022-11-30
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
Evolocumab Pre-filled Syringe, Evolocumab AI/pen - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3CompletedAmgen1492013-04-182018-11-29
Bezafibrate Plus Berberine in Mixed Dyslipidemia
Berberine, Bezafibrate, Berberine plus Bezafibrate - Mixed Dyslipidemia
Phase 3CompletedUniversity of Guadalajara362013-04-012023-02-24
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM) - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3TerminatedMerck Sharp & Dohme LLC11392011-05-012019-02-06
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
Extended-release niacin/laropiprant (ERN/LRPT), Placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3TerminatedMerck Sharp & Dohme LLC11732011-03-012024-05-22
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
ABT-335, placebo, atorvastatin - Dyslipidemias, Coronary Heart Disease
Phase 3CompletedAbbott5432008-02-012011-06-13
Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)
Comparator: simvastatin, niacin (+) laropiprant, Comparator: atorvastatin calcium - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3CompletedMerck Sharp & Dohme LLC12162007-07-012015-03-10
MK-0524B Lipid Study (MK-0524B-063)
Comparator: simvastatin, MK-0524A, Placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3CompletedMerck Sharp & Dohme LLC24142007-06-152019-02-06
A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia
ABT-335, rosuvastatin calcium, simvastatin - Mixed Dyslipidemia
Phase 3CompletedAbbott3102007-06-012012-01-20
An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)
Niacin ER/Simvastatin Tablets, atorvastatin - Hyperlipidemia, Mixed Dyslipidemia
Phase 3CompletedAbbott1992007-04-012011-06-13
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin - Dyslipidemia, Coronary Heart Disease
Phase 3CompletedAbbott19112006-09-012009-07-23
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
ABT-335, Atorvastatin, Placebo - Mixed Dyslipidemia, Coronary Heart Disease
Phase 3CompletedAbbott6132006-03-012009-06-03
Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
ABT-335, Simvastatin, Placebo - Dyslipidemia, Coronary Heart Disease
Phase 3CompletedAbbott6572006-03-012009-06-03
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
ABT-335, Rosuvastatin Calcium, Placebo - Dyslipidemia, Coronary Heart Disease
Phase 3CompletedAbbott14452006-03-012009-06-10

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Hypercholesterolemia (9)  ·  Dyslipidemias (6)  ·  Coronary Disease (5)  ·  Coronary Artery Disease (1)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Hyperlipidemias (1)

Broader conditions

Lipid Metabolism Disorders (15)  ·  Metabolic Diseases (15)  ·  Nutritional and Metabolic Diseases (15)  ·  Dyslipidemias (9)  ·  Hyperlipidemias (9)  ·  Cardiovascular Diseases (6)  ·  Heart Diseases (6)  ·  Myocardial Ischemia (6)  ·  Vascular Diseases (6)  ·  Arterial Occlusive Diseases (1)  ·  Arteriosclerosis (1)  ·  Coronary Disease (1)  ·  Endocrine System Diseases (1)  ·  Glucose Metabolism Disorders (1)

Interventions

Atorvastatin (7)  ·  2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (6)  ·  Simvastatin (6)  ·  Rosuvastatin Calcium (4)  ·  evolocumab (4)  ·  MK-0524 (3)  ·  8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (2)  ·  Ezetimibe (2)  ·  Fenofibrate (2)  ·  Fluvastatin (2)  ·  fenofibric acid (2)  ·  Berberine (1)  ·  Bezafibrate (1)  ·  Niacin (1)  ·  Simcor (1)

Sponsors

Abbott (7)  ·  Amgen (4)  ·  Merck Sharp & Dohme LLC (4)  ·  Novartis (2)  ·  A. Menarini International Licensing S.A. (1)  ·  Addpharma Inc. (1)  ·  Daewon Pharmaceutical Co., Ltd. (1)  ·  Daiichi Sankyo (1)  ·  University of Guadalajara (1)

Countries

United States (10)  ·  Canada (3)  ·  China (2)  ·  Italy (2)  ·  Mexico (2)  ·  South Korea (2)  ·  Spain (2)  ·  Belgium (1)  ·  Germany (1)  ·  Poland (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Kyu Chang Won, M.D., Ph.D (1)  ·  Maureen Kelly, MD (1)  ·  Roopal Thakkar, MD (1)

Results publications

PMID 18783301, PMID 20136164, PMID 20573750, PMID 22263674, PMID 18996523, PMID 19995098, PMID 20518948, PMID 20934572, PMID 21174145, PMID 21401833, PMID 22500948, PMID 27066336, PMID 30953107, PMID 36435949

NIH funding

2025 (2), 2015 (1)